Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy

Current Opinion in Investigational Drugs

Volumn 9, Issue 1, 2008, Pages 101-107

  Pollard, J R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BETA CARBOLINE; BRIVARACETAM; DIAZEPAM; ETIRACETAM; GLYCOPROTEIN; HARKOSERIDE; KAINIC ACID; LAMOTRIGINE; LEVODOPA; MYOCALM; PHENYTOIN; PIRACETAM; SELETRACETAM; SYNAPTIC VESICLE GLYCOPROTEIN 2A; UCB 101596 1; UNCLASSIFIED DRUG; VALPROIC ACID;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISTRIBUTION VOLUME; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EUPHORIA; FATIGUE; HEADACHE; HUMAN; MONOTHERAPY; MOOD CHANGE; NAUSEA; NONHUMAN; PARKINSON DISEASE; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; TREATMENT RESPONSE; WEIGHT GAIN;

ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; PARKINSON DISEASE; PYRROLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38049095254     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 438137 Safety review of adult clinical trial experience with lamotrigine. Messenheimer J, Mullens EL, Giorgi L, Young F Drug Saf 1998 18 4 281-296
2. 482780 UCB'S pharma sector announces promising first results of a new antiepileptic drug candidate. UCB SA PRESS RELEASE 2003 March 21
3. 535278 UCB's Keppra analog enters phase I. UCB SA Pres Release 2004 April 28
4. 593753 The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B PROC NATL ACAD SCI USA 2004 101 26 9861-9866
5. 633198 Seletracetam (UCB 44212) reduces l-dopa-induced dyskinesia (chorea/dystonia) in the MPTP-lesioned macaque model of Parkinson's disease. Michel A, Ravenscroft P, Hill MP, Bezard E, Crossman AR, Grimee R, Klitgaard H ABSTR SOC NEUROSCI 2005 35 Abs 88.9
6. 636406 Distinct ability of seletracetam and brivaracetam to counteract epileptiform synchrony versus excitability in vitro. Margineanu G, Klitgaard H ABSTR SOC NEUROSCI 2005 35 Abs 969.6
7. 655555 UCB increases revenue by 24% in 2005. UCB SA PRESS RELEASE 2006 March 14
8. 657265 Discovery of seletracetam: A new pyrrolidone derivative with potent antiepileptic properties and high tolerability in rodent models of epilepsy. Kenda B, Matagne A, Talaga A, Michel P ACS 2006 231 MEDI 200
9. 691409 Seletracetam (UCB 44212), a new pyrrolidone derivative, reveals potent activity in in vitro and in vivo models of epilepsy. Matagne A, Margineanu DG, Michel P, Kenda B, Klitgaard H J NEUROL SCI 2005 238 Suppl 1 S133-S134
10. 691410 Seletracetam (UCB 44212), a new pyrrolidone derivative, suppresses seizures in animal models of chronic epilepsy in vivo. Matagne A, Michel P, Kenda B, Klitgaard H EPILEPSIA 2005 46 Suppl 6 121
11. 691411 Seletracetam (UCB 44212), a new pyrrolidone derivative, inhibits epileptiform responses in hippocampal slices in vitro. Margineanu DG, Michel P, Kenda B, Matagne A, Klitgaard H Epilepsia 2005 46 Suppl 6 121
12. 691412 Anticonvulsant action of seletracetam (UCB 44212) in an animal model of status epilepticus. Wasterlain CG, Suchomelova L, Matagne A, Klitgaard H, Mazarati A, Shinmei S, Baldwin R EPILEPSIA 2005 46 Suppl 6 121
13. 2+] increase in rat cortical neurons in vitro. Pisani A, Bonsi P, Martella G, Cuomo D, Klitgaard H, Margineanu DG EPILEPSIA 2005 46 Suppl 8 119-120
14. + currents in rat brain neurons in vitro. Zona C, Niespodziany I, Pieri M, Klitgaard H, Margineanu DG EPILEPSIA 2005 46 Suppl 8 116
15. 691415 Seletracetam (UCB 44212): Effect on inhibitory and excitatory neurotransmission. Rigo JM, Nguyen L, Hans G, Belachew S, Moonen G, Matagne A, Klitgaard H EPILEPSIA 2005 46 Suppl 8 110-111
16. 694078 UCB hosts its first research and development day. UCB SA PRESS RELEASE 2006 September 26
17. 743147 Diverse mechanisms of antiepileptic drugs in the development pipeline. Rogawski MA EPILEPSY RES 2006 69 3 273-294
18. 768746 NCT00422110: A study to evaluate the efficacy and safety of seletracetam in adult patients with refractory partial onset seizures. UCB SA CLINICALTRIALS.GOV 2007 January 11
19. 776238 Seletracetam (UCB 44212). Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N NEUROTHERAPEUTICS 2007 4 1 117-122
20. 776702 Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII). Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T EPILEPSY RES 2007 73 1 1-52 •• This conference proceedings report provides a valuable review of the avialable data on anti-epileptic drugs currently in development.
21. 14C-seletracetam in healthy subjects. Ramael S, Sargentini-Maier M, Toublanc N, Dubin G, Stockis A EPILEPSIA 2006 47 Suppl 3 130
22. 2+" rat hippocampal slice model. Margineanu D, Klitgaard H Epilepsia 2006 47 Suppl 3 74-75
23. 776707 Seletracetam (UCB 44212): Single and multiple rising dose safety, tolerability and pharmacokinetics in healthy subjects. Leese PT, Goldwater DR, Hulhoven R, Salas E, Toublanc N, Chen D, Sargentini-Maier ML, Stockis A Epilepsia 2006 47 Suppl 4 164
24. 776708 Proof of principle of the new AED seletracetam (UCB 44212) in the photosensitivity model. Trenite DKN, Abou-Khalil B, French J, Genton P, Hirsch E, Masnou P, Parain D, Chen D, Hollis A, Mc-Cabe S, Troenaru M et al EPILEPSIA 2006 47 Suppl 4 161-162
25. 776710 Seletracetam single rising dose safety, tolerability and pharmacokinetics in healthy subjects. Goldwater D, Lu Z, Salas E, Toublanc N, Chen D, Sargentini-Maier ML, Stockis A J CLIN PHARMACOL 2006 46 9 Abs 78
26. 776711 Seletracetam multiple dose safety, tolerability and pharmacokinetics in healthy subjects. Leese PT, Hulhoven R, Salas E, Toublanc N, Chen DD, Sargentini-Maier ML, Stockis A J Clin Pharmacol 2006 46 9 Abs 77
27. 807976 New antiepileptic drugs that are second generation to existing antiepileptic drugs. Bialer M EXPERT OPIN INVEST DRUGS 2006 15 6 637-647 •• This excellent review provides expert insight into the pharmacology of anti-epileptic drugs in development.
28. 807988 Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM PROC NATL ACAD SCI USA 1999 96 26 15268-15273
29. 808002 SV2 is the protein receptor for botulinum neurotoxin A. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER SCIENCE 2006 312 5773 592-596
30. 808052 Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. Nagase T, Ishikawa K, Suyama M, Kikuno R, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O DNA RES 1998 5 5 277-286
31. 808950 NCT00175851: Open label trial to study the long-term safety and efficacy of seletracetam for the treatment of epilepsy. UCB SA CLINICALTRIALS.GOV 2007 March 12
32. 808970 Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): Differentiation of levetiracetam from conventional antiepileptic drugs. Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M EPILEPSIA 2005 46 9 1362-1370
33. 808982 Who gets epilepsy?: www.epilepsy.com. Schachter SC INTERNET SITE 2006 October 16
34. 808989 Phenytoin: Drug information provided by Lexi-Comp. Merck & Co Inc COMPANY WORLD WIDE WEB SITE 2007 June 27
35. 809000 Reproductive dysfunction in women with epilepsy: Recommendations for evaluation and management. Bauer J, Isojarvi JI, Herzog AG, Reuber M, Polson D, Tauboll E, Genton P, van der Ven H, Roesing B, Luef GJ, Galimberti CA et al J NEUROL NEUROSURG PSYCHIATRY 2002 73 121-125
36. 816241 UCB: First half-year 2007 financial results. UCB SA PRESS RELEASE 2007 July 26
37. 847500 Lacosamide has a dual mode of action: 1) Selective enhancement of sodium channel slow inactivation. Lees G, Stoehr T, Heers C, Errington AC Soc Neurosci An Meet 2007 37 Abs 166.11
38. 847503 Lacosamide has a dual mode of action: 2) Modulation of collapsin response mediator protein 2 (CRMP-2). Freitag JM, Beyreuther B, Heers C, Stoehr T Soc Neurosci An Meet 2007 37 Abs 166.12
39. 850341 Seletracetam multiple dose safety, tolerability, and pharmacokinetics in healthy subjects. Leese P, Hulhoven R, Salas V, Toublanc N, Chen D, Sargentini-Maier M, Stockis A Epilepsia 2006 47 Suppl 3 497
40. 850342 Seletracetam single rising dose safety: Tolerability and pharmacokinetics in healthy subjects. Goldwater D, Lu Z, Salas V, Toublanc N, Chen D, Sargentini-Maier M, Stockis A Epilepsia 2006 47 Suppl 3 496
41. 851261 The epidemiology of epilepsy revisited. Sander JW CUR OPIN NEUROL 2003 16 2 165-170
42. 851274 Ion channels and epilepsy. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adín J CUR PHARM DESIGN 2005 11 15 1975-2003
43. 851275 Levetiracetam, a new antiepileptic agent: Lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Coupez R, Nicolas JM, Browne TR EPILEPSIA 2003 44 2 171-178
44. 851306 Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M et al HEALTH TECHNOL ASSESS 2005 9 15 1-157